protein

PF4V1 Protein, Human (HEK293, Fc)

HY-P76539

5 μg;10 μg;50 μg;100 μg

55;90;250;420 USD

PF4V1 Protein, Human (HEK293, Fc)

proteins

HEK293

5 μg;10 μg;50 μg;100 μg

55;90;250;420 USD

PF4V1, also known as CXCL4L1, is a non-allelic variant of CXCL4. PF4V1 is a platelet-associated chemokine, and it binds to heparin is much weaker than in the close homolog PF4/CXCL4. PF4V1 is an inhibitor of angiogenesis and inhibitor of endothelial cell chemotaxis. PF4V1 is involved in inflammation, angiogenesis, and cancer [1] [2] . PF4V1 Protein, Human (HEK293, Fc) is produced in HEK293 cells with a C-Terminal Fc-tag. It consists of 104 amino acids (M1-S104).

Human

PF4V1 (CXCL4L1), a CXC chemokine, is originally isolated from thrombin stimulated platelets. Full-length human CXCL4L1/PF-4var is comprised of 104 amino acids. CXCL4L1 seems to be constitutively released by platelets, smooth muscle cells, human aortic and coronary smooth muscle cells and is inducible in monocytes, endothelial and osteosarcoma cells by inflammatory mediators. CXCL4L1 plays a role in inflammation, angiogenesis and cancer [1] [2] [3] . CXCL4 and its non-allelic variant CXCL4L1 are both platelet-derived chemokines. The mature CXCL4L1 protein is composed of 70 amino acids and differs in only three amino acids situated in the carboxy-terminal part of the protein (Pro58 ) Leu, Lys66 ) Glu, Leu67 ) His; CXCL4 ) CXCL4L1). Due to these changes in amino acids, CXCL4L1 is supposed to have a different secondary structure and a lower affinity for heparin. In vivo, weak to strong expression of CXCL4L1 was detected in sarcoma tissue by immunohistochemistry. CXCL4L1 functions as a chemoattractant for activated T cells, NK cells and immature dendritic cells. CXCL4L1 is a more potent angiostatic chemokine compared to CXCL4. Compared to CXCL4, CXCL4L1 is less likely to form heterodimers with fFGF2 and VEGF or to compete for GAG-binding [1] [2] [3] . CXCL4L1 is found to be a more potent angiostatic and anti-tumoral chemokine compared to CXCL4 in various in vitro and in vivo assays. CXCL4L1 (10 ng/mL) is more potent than CXCL4 in inhibiting CXCL8/IL-8- or FGF-2-induced chemotaxis of endothelial cells. Further, CXCL4L1 is induced in human osteosarcoma cells (1.5-3.5 ng/mL) by IL-1β, TNF-α and IL-17A. CXCL4L1 is expressed and functioned in several cancers such as ovarian carcinoma, breast cancer, and pancreatic cancer. Additionally, CXCL4L1 is also strongly detected in colorectal carcinoma tissue samples, whereas CXCL4L1 staining in squamous cell carcinoma of the esophagus is weak to negative [1] [2] [3] .

Platelet factor 4 variant; CXCL4L1; PF4var1; SCYB4V1

Greater than 95% as determined by reducing SDS-PAGE.

Lyophilized from a 0.2 μm filtered solution of 20 mM PB, 150 mM NaCl, pH 7.4.

Room temperature in continental US; may vary elsewhere.